Literature DB >> 1873225

Prothrombin fragment 1 + 2, thrombin-antithrombin III complexes and D-dimers in acute deep vein thrombosis: effects of heparin treatment.

M Estivals1, H Pelzer, P Sie, J Pichon, H Boccalon, B Boneu.   

Abstract

Plasma levels of prothrombin fragment 1 + 2 (F 1 + 2), of thrombin-antithrombin III complexes (TAT) and of D-dimers were evaluated at several time intervals in 15 patients affected by acute proximal deep vein thrombosis, complicated or not by pulmonary embolism, and treated by conventional heparin therapy for 9 d. The mean levels of the three markers remained significantly increased throughout the period of observation, except for F 1 + 2 on day 9, when compared to normal values established in a population of normal healthy blood donors. However, whereas heparin significantly decreased the plasma levels of F 1 + 2 and of TAT complexes in less than 3 d. D-dimer levels were not significantly altered. Significant correlations were observed between the plasma levels of the three markers but they were not correlated to the actual intensity of heparin treatment evaluated as the activated partial thromboplastin time prolongation. These results indicate that heparin improves the hypercoagulable state associated with a deep vein thrombosis within the first days of treatment as indicated by TAT and F 1 + 2. They also account for the performances of D-dimer assay for the diagnosis of deep vein thrombosis in patients already receiving heparin, a common situation in routine hospital practice.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1873225     DOI: 10.1111/j.1365-2141.1991.tb04458.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Laboratory Measurement of Thrombin Activity--What Every Clinician Scientist Needs to Know.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

2.  Influence of blood sampling from venipunctures and catheter systems on serial determinations of prothrombin activation fragment 1 + 2 and thrombin-antithrombin III complex.

Authors:  G Hafner; H Schinzel; W Ehrenthal; C Wagner; U Konheiser; R Zotz; J Lotz; R Blank; L S Weilemann; W Prellwitz
Journal:  Ann Hematol       Date:  1993-09       Impact factor: 3.673

3.  An in situ inferior vena cava ligation-stenosis model to study thrombin generation rates with flow.

Authors:  Wei Yin; Andrew Dimatteo; Andrew Kumpfbeck; Stephen Leung; Marina Fandaros; Bryan Musmacker; David A Rubenstein; Mary D Frame
Journal:  Thromb J       Date:  2022-05-25

4.  Sclerotherapy for varicose veins of the lower legs in patients with dysplasminogenemia.

Authors:  M Ikeda; T Kawasaki; J Kambayashi; S Iwamoto; N Shinoki; T Nakamura; T Shibuya; M Monden
Journal:  Surg Today       Date:  1997       Impact factor: 2.540

5.  Label-Free Kinetic Studies of Hemostasis-Related Biomarkers Including D-Dimer Using Autologous Serum Transfusion.

Authors:  Heiko Rühl; Christina Berens; Anna Winterhagen; Jens Müller; Johannes Oldenburg; Bernd Pötzsch
Journal:  PLoS One       Date:  2015-12-14       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.